UCB (OTCMKTS:UCBJY) Stock Passes Below 200-Day Moving Average – Here’s Why

UCB SA (OTCMKTS:UCBJY) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $145.86 and traded as low as $122.54. UCB shares last traded at $122.60, with a volume of 26,717 shares trading hands.

Wall Street Analysts Forecast Growth

UCBJY has been the subject of a number of research analyst reports. Jefferies Financial Group upgraded shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. Barclays cut shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Finally, Zacks Research raised shares of UCB from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy”.

UCB Stock Down 2.8%

The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The stock has a 50 day simple moving average of $140.16 and a 200-day simple moving average of $145.86.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.